Clinical Trials Browser

Not yet recruiting × Tacrolimus × 1 year × Clear all

Pseudomyxoma Peritonei

NCT07349771 2026-01-20

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Phase 2 Not yet recruiting

72 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT07302776 2025-12-24

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Phase 1 Not yet recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Not yet recruiting

15 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

TRANSCAPE

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant